Clidinium bromide

Clidinium bromide (INN) is an anticholinergic (specifically a muscarinic antagonist) drug.[1] It may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines. It is commonly prescribed in combination with chlordiazepoxide (a benzodiazepine derivative) using the brand name Librax.

Not to be confused with Acridinium bromide or Aclidinium bromide.
Clidinium bromide
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa601036
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    BioavailabilityLow
    ExcretionRenal and biliary
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC22H26NO3+
    Molar mass352.447 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Uses

    Peptic ulcer disease

    Used in fixed combination with chlordiazepoxide as adjunctive therapy in the treatment of peptic ulcer disease; however, no conclusive data that antimuscarinics aid in the healing, decrease the rate of recurrence, or prevent complications of peptic ulcers.[2]

    With the advent of more effective therapies for the treatment of peptic ulcer disease, antimuscarinics have only limited usefulness in this condition.

    GI motility disturbances

    Used in fixed combination with chlordiazepoxide in the treatment of functional GI motility disturbances (e.g., irritable bowel syndrome).

    Has limited efficacy in treatment of GI motility disturbance and should only be used if other measures (e.g., diet, sedation, counseling, amelioration of environmental factors) have been of little or no benefit.

    Acute enterocolitis

    Used in fixed combination with chlordiazepoxide in the treatment of acute enterocolitis. However, antimuscarinics should be used with extreme caution in patients with diarrhea or ulcerative colitis.

    Mechanism of action

    Clidinium inhibits muscarinic acetylcholine receptors on smooth muscles, secretory glands, and in the central nervous system to relax smooth muscle and decrease biliary tract secretions.[3]

    References
    1. "Clidinium bromide". Drugs.com. Retrieved August 24, 2013.
    2. "Clidinium Bromide Monograph". Drugs.com. Retrieved August 24, 2013.
    3. 2014 Nurses Drug Handbook (13th ed.). Burlington, MA: Jones & Bartlett Learning. 2014. pp. 245-6. ISBN 978-1-284-03115-7.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.